Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

COVID-19

Free Subscription 11.03.2024 3 Ann Intern Med 5 Antiviral Res 3 BMJ 2 Clin Infect Dis 1 Infect Control Hosp Epidemiol 3 Int J Infect Dis 1 Intensive Care Med 5 J Infect 7 J Med Virol 1 J Travel Med 1 J Virol 3 JAMA 1 Lancet Infect Dis 1 MMWR Morb Mortal Wkly Rep 4 Zhonghua Jie He He Hu Xi Za Zhi

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Intern Med

1. KIM MS, Lee H, Lee SW, Kwon R, et al
   Long-Term Autoimmune Inflammatory Rheumatic Outcomes of COVID-19 : A Binational Cohort Study.
   Ann Intern Med. 2024 Mar 5. doi: 10.7326/M23-1831.
   PubMed         Abstract available
   
   
2. GRANWEHR BP
   In mild to moderate COVID-19, VV116 safely reduced time to sustained clinical symptom resolution.
   Ann Intern Med. 2024 Mar 5. doi: 10.7326/J24-0006.
   PubMed         Abstract available
   
   
3. CAI J, Pirzada A, Baldoni PL, Heiss G, et al
   Cumulative All-Cause Mortality in Diverse Hispanic/Latino Adults : A Prospective, Multicenter Cohort Study.
   Ann Intern Med. 2024 Mar 5. doi: 10.7326/M23-1990.
   PubMed         Abstract available
   
   

   
   Antiviral Res

4. BANDYSZEWSKA M, Ambrozek-Latecka M, Hoser G, Grzanka M, et al
   SARS-CoV-2 virus-like particle variants alpha and delta mimic the native viruses in their differential inflammasome activating potential.
   Antiviral Res. 2024 Mar 5:105857. doi: 10.1016/j.antiviral.2024.105857.
   PubMed         Abstract available
   
   
5. WANG W, Wang S, Meng X, Zhao Y, et al
   A virus-like particle candidate vaccine based on CRISPR/Cas9 gene editing technology elicits broad-spectrum protection against SARS-CoV-2.
   Antiviral Res. 2024 Mar 4:105854. doi: 10.1016/j.antiviral.2024.105854.
   PubMed         Abstract available
   
   
6. KLEVANSKI M, Kim H, Heilemann M, Kuner T, et al
   Glycan-directed SARS-CoV-2 inhibition by leek extract and lectins with insights into the mode-of-action of Concanavalin A.
   Antiviral Res. 2024 Mar 4:105856. doi: 10.1016/j.antiviral.2024.105856.
   PubMed         Abstract available
   
   
7. SCHREIBER A, Rodner F, Oberberg N, Anhlan D, et al
   The host-targeted antiviral drug Zapnometinib exhibits a high barrier to the development of SARS-CoV-2 resistance.
   Antiviral Res. 2024 Mar 2:105840. doi: 10.1016/j.antiviral.2024.105840.
   PubMed         Abstract available
   
   
8. NOBORI H, Baba K, Kuroda T, Baba K, et al
   Prophylactic effect of ensitrelvir in mice infected with SARS-CoV-2.
   Antiviral Res. 2024;224:105852.
   PubMed         Abstract available
   
   

   
   BMJ

9. WATTERSON A
   What we did not learn at the covid inquiry in Scotland: a gap analysis.
   BMJ. 2024;384:q491.
   PubMed        
   
   
10. 
    Analysis of peer reviewers' response to invitations by gender and geographical region: cohort study of manuscripts reviewed at 21 biomedical journals before and during covid-19 pandemic.
    BMJ. 2024;384:q528.
    PubMed        
    
    
11. AGIUS RM
    UK workers during the pandemic: inadequate protection and, consequently, increased risk.
    BMJ. 2024;384:q508.
    PubMed        
    
    

    
    Clin Infect Dis

12. WENZEL RP
    Reflections on COVID-19: Solitude and Isolation.
    Clin Infect Dis. 2024 Mar 7:ciae099. doi: 10.1093.
    PubMed        
    
    
13. HUYGENS S, GeurtsvanKessel C, Gharbharan A, Bogers S, et al
    Clinical and Virological Outcome of Monoclonal Antibody Therapies Across Severe Acute Respiratory Syndrome Coronavirus 2 Variants in 245 Immunocompromised Patients: A Multicenter Prospective Cohort Study.
    Clin Infect Dis. 2024 Mar 6:ciae026. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    Infect Control Hosp Epidemiol

14. GUSSIN GM, Singh RD, Gohil SK, Saavedra R, et al
    Impact of universal chlorhexidine bathing with or without COVID-19 intensive training on staff and resident COVID-19 case rates in nursing homes.
    Infect Control Hosp Epidemiol. 2024 Mar 5:1-4. doi: 10.1017/ice.2024.
    PubMed         Abstract available
    
    

    
    Int J Infect Dis

15. BOUWMANS P, Malahe SRK, Messchendorp AL, Vart P, et al
    Post COVID-19 condition imposes significant burden in patients with advanced chronic kidney disease: a nested case-control study.
    Int J Infect Dis. 2024 Feb 28:106990. doi: 10.1016/j.ijid.2024.106990.
    PubMed         Abstract available
    
    
16. REES C, Swift B, Haldar P
    State of art of the detection of M. tuberculosis during TB infection by blood tests using the phage technology.
    Int J Infect Dis. 2024 Mar 4:106991. doi: 10.1016/j.ijid.2024.106991.
    PubMed         Abstract available
    
    
17. AGUILAR TICONA JP, Xiao M, Li D, Nery JN, et al
    Corrigendum to "Extensive transmission of SARS-CoV-2 BQ.1* variant in a population with high levels of hybrid immunity: A prevalence survey" [International Journal of Infectious Diseases 139 (2024) 159-167].
    Int J Infect Dis. 2024;141:106964.
    PubMed        
    
    

    
    Intensive Care Med

18. SALVE G, Mongodi S, Mangiagalli M, Tintim Lobato C, et al
    Memories of ICU stay in patients admitted for severe COVID-19.
    Intensive Care Med. 2024 Mar 4. doi: 10.1007/s00134-024-07365.
    PubMed        
    
    

    
    J Infect

19. POWELL AA, Dowell AC, Moss P, Ladhani SN, et al
    Current state of COVID-19 in children: 4 years on.
    J Infect. 2024 Mar 1:106134. doi: 10.1016/j.jinf.2024.106134.
    PubMed         Abstract available
    
    
20. FATLY ZA, Betjes MGH, Dik WA, Fouchier RAM, et al
    Mycophenolate mofetil hampers antibody responses to a broad range of vaccinations in kidney transplant recipients: results from a randomized controlled study.
    J Infect. 2024 Mar 1:106133. doi: 10.1016/j.jinf.2024.106133.
    PubMed         Abstract available
    
    
21. MEERAUS W, Joy M, Ouwens M, Taylor KS, et al
    AZD1222 effectiveness against severe COVID-19 in individuals with comorbidity or frailty: the RAVEN cohort study.
    J Infect. 2024 Feb 29:106129. doi: 10.1016/j.jinf.2024.106129.
    PubMed         Abstract available
    
    
22. HAYWARD G, Yu LM, Little P, Gbinigie O, et al
    Ivermectin for COVID-19 in adults in the community (PRINCIPLE): an open, randomised, controlled, adaptive platform trial of short- and longer-term outcomes.
    J Infect. 2024 Feb 29:106130. doi: 10.1016/j.jinf.2024.106130.
    PubMed         Abstract available
    
    
23. LIU P, Cai J, Tian H, Li J, et al
    Intra-host genetic diversity of SARS-CoV-2 Omicron variants in children.
    J Infect. 2024 Feb 29:106132. doi: 10.1016/j.jinf.2024.106132.
    PubMed        
    
    

    
    J Med Virol

24. CHEN IW, Lin HJ, Lin YT, Hung KC, et al
    Comment on "The association of sickle cell disorder with adverse outcomes in COVID-19 patients: A meta-analysis".
    J Med Virol. 2024;96:e29495.
    PubMed        
    
    
25. LIU Y, Li M, Cui T, Chen Z, et al
    A superior heterologous prime-boost vaccination strategy against COVID-19: A bivalent vaccine based on yeast-derived RBD proteins followed by a heterologous vaccine.
    J Med Virol. 2024;96:e29454.
    PubMed         Abstract available
    
    
26. KIM JW, Lee JH, Kim HJ, Heo K, et al
    Empowering SARS-CoV-2 variant neutralization with a bifunctional antibody engineered with tandem heptad repeat 2 peptides.
    J Med Virol. 2024;96:e29506.
    PubMed         Abstract available
    
    
27. ZHANG R, Yan H, Zhou J, Yan G, et al
    Improved fluorescence-based assay for rapid screening and evaluation of SARS-CoV-2 main protease inhibitors.
    J Med Virol. 2024;96:e29498.
    PubMed         Abstract available
    
    
28. XIONG N, Sun Q
    Identifying COVID-19 subtypes by single-sample gene set enrichemnt analysis and providing guidance for sensitive drug selection.
    J Med Virol. 2024;96:e29497.
    PubMed         Abstract available
    
    
29. WU N, Chen Z, Zha G, Deng Z, et al
    Clinical and immunological features of COVID-19 in patients with anti-MDA5 dermatomyositis during the omicron wave in Chongqing, China.
    J Med Virol. 2024;96:e29493.
    PubMed         Abstract available
    
    
30. 
    Retraction: "Safety and immunogenicity of a recombinant receptor-binding domain-based protein subunit vaccine (Noora vaccine) against COVID-19 in adults: A randomized, double-blind, placebo-controlled, Phase 1 trial".
    J Med Virol. 2024;96:e29509.
    PubMed         Abstract available
    
    

    
    J Travel Med

31. WANNIGAMA DL, Amarasiri M, Phattharapornjaroen P, Hurst C, et al
    Wastewater-based epidemiological surveillance of SARS-CoV-2 new variants BA.2.86 and offspring JN.1 in south and Southeast Asia.
    J Travel Med. 2024 Mar 4:taae040. doi: 10.1093.
    PubMed        
    
    

    
    J Virol

32. ZHENG T, Shen B, Bai Y, Li E, et al
    The PKA-CREB1 axis regulates coronavirus proliferation by viral helicase nsp13 association.
    J Virol. 2024 Mar 6:e0156523. doi: 10.1128/jvi.01565.
    PubMed         Abstract available
    
    

    
    JAMA

33. HARRIS E
    Better Outcomes When Kidney Damage Is From COVID-19.
    JAMA. 2024 Mar 6. doi: 10.1001/jama.2024.1574.
    PubMed        
    
    
34. HARRIS E
    HPV Vaccination Rates Stagnated During COVID-19 Pandemic.
    JAMA. 2024 Mar 6. doi: 10.1001/jama.2024.1569.
    PubMed        
    
    
35. HARRIS E
    Millions of US Children Experience Range of Long COVID Effects.
    JAMA. 2024;331:726.
    PubMed        
    
    

    
    Lancet Infect Dis

36. KOUTSAKOS M, Rockman S, Krammer F
    Is eradication of influenza B viruses possible?
    Lancet Infect Dis. 2024 Mar 4:S1473-3099(24)00132.
    PubMed        
    
    

    
    MMWR Morb Mortal Wkly Rep

37. MOLINE HL, Tannis A, Toepfer AP, Williams JV, et al
    Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024.
    MMWR Morb Mortal Wkly Rep. 2024;73:209-214.
    PubMed         Abstract available
    
    

    
    Zhonghua Jie He He Hu Xi Za Zhi

38. GAO HB, Zhang J
    [Analysis of prognostic factors in patients with COVID-19 infection].
    Zhonghua Jie He He Hu Xi Za Zhi. 2024;47:296-300.
    PubMed         Abstract available
    
    
39. GUO JW, Xiao Y
    [Impact of COVID-19 on the treatment of sleep medicine].
    Zhonghua Jie He He Hu Xi Za Zhi. 2024;47:292-296.
    PubMed         Abstract available
    
    
40. YU D, Huang WQ, Zhan YZ, Xiao GH, et al
    [Diaphragmatic dysfunction post-COVID-19 infection: report of two cases].
    Zhonghua Jie He He Hu Xi Za Zhi. 2024;47:244-248.
    PubMed         Abstract available
    
    
41. CHEN RX, Mai YL, Shen KN, Zhang T, et al
    [A case of follicular lymphoma with recurrent fever and pulmonary infiltrates].
    Zhonghua Jie He He Hu Xi Za Zhi. 2024;47:222-227.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO COVID-19 is free of charge.